Symbols / CSTL
CSTL Chart
About
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 930.53M |
| Enterprise Value | 680.13M | Income | -12.24M | Sales | 343.53M |
| Book/sh | 16.02 | Cash/sh | 9.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 823 | IPO | — |
| P/E | — | Forward P/E | -49.94 | PEG | — |
| P/S | 2.71 | P/B | 1.99 | P/C | — |
| EV/EBITDA | 86.87 | EV/Sales | 1.98 | Quick Ratio | 6.12 |
| Current Ratio | 6.46 | Debt/Eq | 7.95 | LT Debt/Eq | — |
| EPS (ttm) | -0.44 | EPS next Y | -0.64 | EPS Growth | — |
| Revenue Growth | -3.20% | Earnings | 2026-02-26 | ROA | -1.72% |
| ROE | -2.70% | ROIC | — | Gross Margin | 79.94% |
| Oper. Margin | -8.19% | Profit Margin | -3.56% | Shs Outstand | 29.19M |
| Shs Float | 24.57M | Short Float | 5.33% | Short Ratio | 3.38 |
| Short Interest | — | 52W High | 44.28 | 52W Low | 14.59 |
| Beta | 1.05 | Avg Volume | 389.08K | Volume | 662.20K |
| Target Price | $48.12 | Recom | Strong_buy | Prev Close | $30.83 |
| Price | $31.88 | Change | 3.41% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$48.13
Mean price target
2. Current target
$31.88
Latest analyst target
3. DCF / Fair value
$17.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.88
Low
$41.00
High
$52.00
Mean
$48.13
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-26 | main | Guggenheim | Buy → Buy | $47 |
| 2026-01-12 | main | Lake Street | Buy → Buy | $52 |
| 2026-01-05 | main | Guggenheim | Buy → Buy | $43 |
| 2025-12-22 | main | Canaccord Genuity | Buy → Buy | $50 |
| 2025-12-12 | main | BTIG | Buy → Buy | $50 |
| 2025-11-05 | main | BTIG | Buy → Buy | $38 |
| 2025-11-04 | main | Baird | Outperform → Outperform | $41 |
| 2025-09-09 | main | Canaccord Genuity | Buy → Buy | $37 |
| 2025-05-21 | main | Scotiabank | Sector Outperform → Sector Outperform | $40 |
| 2025-05-06 | main | Lake Street | Buy → Buy | $35 |
| 2025-05-06 | main | Canaccord Genuity | Buy → Buy | $37 |
| 2025-02-28 | main | Baird | Outperform → Outperform | $37 |
| 2025-01-02 | reit | Stephens & Co. | Overweight → Overweight | $41 |
| 2024-11-06 | main | Scotiabank | Sector Outperform → Sector Outperform | $44 |
| 2024-11-05 | main | Lake Street | Buy → Buy | $40 |
| 2024-11-05 | main | Keybanc | Overweight → Overweight | $36 |
| 2024-11-05 | main | Baird | Outperform → Outperform | $39 |
| 2024-10-29 | main | Canaccord Genuity | Buy → Buy | $42 |
| 2024-10-14 | main | BTIG | Buy → Buy | $40 |
| 2024-08-06 | reit | Stephens & Co. | Overweight → Overweight | $37 |
- Castle Biosciences Reports 37% Increase in Core Test Reports for 2025, Achieving $344 Million in Revenue - Quiver Quantitative hu, 26 Feb 2026 21
- Castle Biosciences (NASDAQ:CSTL) Announces Earnings Results - MarketBeat Fri, 27 Feb 2026 00
- Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Australia hu, 26 Feb 2026 23
- Castle Biosciences (CSTL) swings to 2025 loss as margins compress - Stock Titan hu, 26 Feb 2026 21
- Castle Biosciences Posts Modest 2025 Growth Amid Headwinds - TipRanks hu, 26 Feb 2026 21
- Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss - Finviz hu, 26 Feb 2026 16
- IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Zacks Investment Research hu, 26 Feb 2026 14
- Castle Biosciences (CSTL) Earnings Transcript - AOL.com hu, 26 Feb 2026 21
- Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 49.91% Upside Potential for Investors - DirectorsTalk Interviews Fri, 06 Feb 2026 08
- Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st hu, 06 Nov 2025 08
- ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance - Finviz hu, 26 Feb 2026 17
- Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat hu, 26 Feb 2026 06
- Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance hu, 19 Feb 2026 15
- New skin test steers severe eczema patients to faster JAK drug relief - Stock Titan hu, 19 Feb 2026 22
- Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change - Zacks Investment Research hu, 26 Feb 2026 15
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4017 | 158757.0 | — | Sale at price 37.82 - 39.91 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 1 | 4017 | 160732.0 | — | Sale at price 40.01 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-01-20 00:00:00 | D |
| 2 | 62219 | — | — | Stock Award(Grant) at price 0.00 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-01-12 00:00:00 | D |
| 3 | 8124 | — | — | Stock Award(Grant) at price 0.00 per share. | STOKES FRANKLIN M. | Chief Financial Officer | — | 2026-01-12 00:00:00 | D |
| 4 | 9207 | — | — | Stock Award(Grant) at price 0.00 per share. | OELSCHLAGER KRISTEN M | Chief Operating Officer | — | 2026-01-12 00:00:00 | D |
| 5 | 9207 | — | — | Stock Award(Grant) at price 0.00 per share. | JUVENAL TOBIN W | Officer | — | 2026-01-12 00:00:00 | D |
| 6 | 4017 | 155694.0 | — | Sale at price 38.09 - 40.10 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 7 | 830 | 33490.0 | — | Sale at price 40.35 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2025-12-22 00:00:00 | D |
| 8 | 14888 | 585292.0 | — | Sale at price 39.31 per share. | OELSCHLAGER KRISTEN M | Chief Operating Officer | — | 2025-12-17 00:00:00 | D |
| 9 | 509 | 20380.0 | — | Sale at price 40.04 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 468.69K | 0.00 |
| TaxRateForCalcs | 0.15 | 0.21 | 0.03 | 0.22 |
| NormalizedEBITDA | 38.14M | -45.02M | -76.63M | -36.60M |
| TotalUnusualItems | 0.00 | 0.00 | 18.29M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | 18.29M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 18.25M | -57.47M | -67.14M | -31.29M |
| ReconciledDepreciation | 16.00M | 12.33M | 10.54M | 3.41M |
| ReconciledCostOfRevenue | 55.31M | 41.66M | 29.73M | 14.37M |
| EBITDA | 38.14M | -45.02M | -58.34M | -36.60M |
| EBIT | 22.14M | -57.35M | -68.89M | -40.01M |
| NetInterestIncome | 12.34M | 10.61M | 3.95M | 67.00K |
| InterestExpense | 577.00K | 11.00K | 17.00K | 1.00K |
| InterestIncome | 12.92M | 10.62M | 3.97M | 68.00K |
| NormalizedIncome | 18.25M | -57.47M | -84.96M | -31.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 18.25M | -57.47M | -67.14M | -31.29M |
| TotalExpenses | 323.40M | 287.76M | 228.18M | 134.16M |
| TotalOperatingIncomeAsReported | 8.67M | -67.98M | -72.86M | -40.08M |
| DilutedAverageShares | 29.25M | 26.80M | 26.05M | 25.14M |
| BasicAverageShares | 27.78M | 26.80M | 26.05M | 25.14M |
| DilutedEPS | 0.62 | -2.14 | -2.58 | -1.24 |
| BasicEPS | 0.66 | -2.14 | -2.58 | -1.24 |
| DilutedNIAvailtoComStockholders | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncomeCommonStockholders | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncome | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncomeIncludingNoncontrollingInterests | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncomeContinuousOperations | 18.25M | -57.47M | -67.14M | -31.29M |
| TaxProvision | 3.32M | 101.00K | -1.77M | -8.72M |
| PretaxIncome | 21.56M | -57.37M | -68.90M | -40.01M |
| OtherIncomeExpense | 555.00K | 18.29M | ||
| OtherNonOperatingIncomeExpenses | 555.00K | |||
| SpecialIncomeCharges | 0.00 | 0.00 | 18.29M | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | -18.29M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 12.34M | 10.61M | 3.95M | 67.00K |
| InterestExpenseNonOperating | 577.00K | 11.00K | 17.00K | 1.00K |
| InterestIncomeNonOperating | 12.92M | 10.62M | 3.97M | 68.00K |
| OperatingIncome | 8.67M | -67.98M | -91.14M | -40.08M |
| OperatingExpense | 263.19M | 242.78M | 196.17M | 118.34M |
| DepreciationAmortizationDepletionIncomeStatement | 11.11M | 9.01M | 8.27M | 1.96M |
| DepreciationAndAmortizationInIncomeStatement | 11.11M | 9.01M | 8.27M | 1.96M |
| Amortization | 11.11M | 9.01M | 8.27M | 1.96M |
| AmortizationOfIntangiblesIncomeStatement | 11.11M | 9.01M | 8.27M | 1.96M |
| ResearchAndDevelopment | 52.04M | 53.62M | 44.90M | 29.65M |
| SellingGeneralAndAdministration | 200.05M | 180.15M | 143.00M | 86.74M |
| SellingAndMarketingExpense | 123.47M | 113.66M | 86.61M | |
| GeneralAndAdministrativeExpense | 76.58M | 66.50M | 56.40M | |
| OtherGandA | 76.58M | 66.50M | 56.40M | |
| GrossProfit | 271.86M | 174.81M | 105.03M | 78.26M |
| CostOfRevenue | 60.20M | 44.98M | 32.01M | 15.82M |
| TotalRevenue | 332.07M | 219.79M | 137.04M | 94.08M |
| OperatingRevenue | 332.07M | 219.79M | 137.04M | 94.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 28.48M | 27.41M | 26.55M | 25.38M |
| ShareIssued | 28.48M | 27.41M | 26.55M | 25.38M |
| TotalDebt | 26.34M | 15.34M | 13.40M | 8.20M |
| TangibleBookValue | 349.61M | 273.93M | 272.80M | 322.82M |
| InvestedCapital | 465.86M | 391.27M | 399.15M | 411.74M |
| WorkingCapital | 310.76M | 247.97M | 256.16M | 328.86M |
| NetTangibleAssets | 349.61M | 273.93M | 272.80M | 322.82M |
| CapitalLeaseObligations | 16.32M | 15.34M | 13.40M | 8.20M |
| CommonStockEquity | 455.83M | 391.27M | 399.15M | 411.74M |
| TotalCapitalization | 465.58M | 391.27M | 399.15M | 411.74M |
| TotalEquityGrossMinorityInterest | 455.83M | 391.27M | 399.15M | 411.74M |
| StockholdersEquity | 455.83M | 391.27M | 399.15M | 411.74M |
| GainsLossesNotAffectingRetainedEarnings | 230.00K | 136.00K | -381.00K | 0.00 |
| OtherEquityAdjustments | 230.00K | 136.00K | -381.00K | |
| RetainedEarnings | -200.13M | -218.37M | -160.91M | -93.77M |
| AdditionalPaidInCapital | 655.70M | 609.48M | 560.41M | 505.48M |
| CapitalStock | 28.00K | 27.00K | 27.00K | 25.00K |
| CommonStock | 28.00K | 27.00K | 27.00K | 25.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 75.40M | 62.07M | 48.18M | 50.83M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.01M | 14.40M | 12.05M | 25.95M |
| OtherNonCurrentLiabilities | 18.29M | |||
| NonCurrentDeferredLiabilities | 1.61M | 206.00K | 428.00K | 635.00K |
| NonCurrentDeferredRevenue | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 1.61M | 206.00K | 428.00K | 635.00K |
| LongTermDebtAndCapitalLeaseObligation | 24.40M | 14.20M | 11.62M | 7.02M |
| LongTermCapitalLeaseObligation | 14.66M | 14.20M | 11.62M | 7.02M |
| LongTermDebt | 9.74M | |||
| CurrentLiabilities | 49.39M | 47.67M | 36.13M | 24.89M |
| OtherCurrentLiabilities | 774.00K | 606.00K | 415.00K | 663.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 1.94M | 1.14M | 1.78M | 1.18M |
| CurrentCapitalLeaseObligation | 1.67M | 1.14M | 1.78M | 1.18M |
| CurrentDebt | 278.00K | |||
| OtherCurrentBorrowings | 278.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 33.78M | 29.84M | 25.26M | 16.24M |
| PayablesAndAccruedExpenses | 12.89M | 16.08M | 8.68M | 6.80M |
| CurrentAccruedExpenses | 4.92M | 5.41M | 3.95M | 4.25M |
| Payables | 7.98M | 10.67M | 4.73M | 2.55M |
| TotalTaxPayable | 1.08M | 401.00K | 37.00K | 695.00K |
| AccountsPayable | 6.90M | 10.27M | 4.73M | 2.55M |
| TotalAssets | 531.24M | 453.34M | 447.33M | 462.57M |
| TotalNonCurrentAssets | 171.08M | 157.71M | 155.04M | 108.83M |
| OtherNonCurrentAssets | 1.23M | 1.44M | 1.11M | 1.72M |
| NonCurrentAccountsReceivable | 918.00K | 1.19M | 1.09M | 1.31M |
| GoodwillAndOtherIntangibleAssets | 106.23M | 117.33M | 126.35M | 88.92M |
| OtherIntangibleAssets | 95.54M | 106.64M | 115.66M | 88.92M |
| Goodwill | 10.69M | 10.69M | 10.69M | 0.00 |
| NetPPE | 62.71M | 37.74M | 26.50M | 16.88M |
| AccumulatedDepreciation | -12.83M | -8.11M | -7.85M | -3.04M |
| GrossPPE | 75.54M | 45.85M | 34.34M | 19.93M |
| Leases | 14.62M | 9.99M | 5.17M | 5.04M |
| ConstructionInProgress | 9.61M | 637.00K | 1.27M | 27.00K |
| OtherProperties | 35.22M | 28.78M | 21.90M | 11.11M |
| MachineryFurnitureEquipment | 8.85M | 6.45M | 6.00M | 3.75M |
| LandAndImprovements | 7.25M | 0.00 | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 360.15M | 295.63M | 292.29M | 353.74M |
| OtherCurrentAssets | 7.67M | 6.29M | 6.21M | 4.81M |
| PrepaidAssets | 4.81M | |||
| Inventory | 8.13M | 7.94M | 3.98M | 2.02M |
| Receivables | 51.22M | 38.30M | 23.48M | 17.28M |
| AccountsReceivable | 51.22M | 38.30M | 23.48M | 17.28M |
| CashCashEquivalentsAndShortTermInvestments | 293.13M | 243.10M | 258.62M | 329.63M |
| OtherShortTermInvestments | 173.42M | 144.26M | 135.68M | 0.00 |
| CashAndCashEquivalents | 119.71M | 98.84M | 122.95M | 329.63M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 36.54M | -19.25M | -47.29M | -22.47M |
| RepaymentOfDebt | -97.00K | -142.00K | -122.00K | -8.00K |
| IssuanceOfDebt | 10.00M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -28.33M | -13.62M | -5.63M | -3.48M |
| InterestPaidSupplementalData | 434.00K | 11.00K | 16.00K | 1.00K |
| IncomeTaxPaidSupplementalData | 2.50M | 198.00K | 120.00K | 16.00K |
| EndCashPosition | 119.71M | 98.84M | 122.95M | 329.63M |
| BeginningCashPosition | 98.84M | 122.95M | 329.63M | 409.85M |
| ChangesInCash | 20.87M | -24.11M | -206.69M | -80.22M |
| FinancingCashFlow | 6.14M | -2.30M | 1.51M | 5.42M |
| CashFlowFromContinuingFinancingActivities | 6.14M | -2.30M | 1.51M | 5.42M |
| NetOtherFinancingCharges | -8.76M | -5.13M | -1.69M | -1.12M |
| ProceedsFromStockOptionExercised | 5.00M | 2.98M | 3.33M | 6.55M |
| NetCommonStockIssuance | 0.00 | |||
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | 9.90M | -142.00K | -122.00K | -8.00K |
| NetLongTermDebtIssuance | 9.90M | -142.00K | -122.00K | -8.00K |
| LongTermDebtPayments | -97.00K | -142.00K | -122.00K | -8.00K |
| LongTermDebtIssuance | 10.00M | 0.00 | 0.00 | |
| InvestingCashFlow | -50.14M | -16.18M | -166.54M | -66.66M |
| CashFlowFromContinuingInvestingActivities | -50.14M | -16.18M | -166.54M | -66.66M |
| NetOtherInvestingChanges | 547.00K | -63.18M | ||
| NetInvestmentPurchaseAndSale | -21.83M | -2.58M | -134.69M | 0.00 |
| SaleOfInvestment | 183.90M | 186.50M | 0.00 | |
| PurchaseOfInvestment | -205.73M | -189.07M | -134.69M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -26.97M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -26.97M | 0.00 |
| NetPPEPurchaseAndSale | -28.31M | -13.61M | -5.44M | -3.47M |
| SaleOfPPE | 18.00K | 13.00K | 195.00K | 10.00K |
| PurchaseOfPPE | -28.33M | -13.62M | -5.63M | -3.48M |
| OperatingCashFlow | 64.87M | -5.63M | -41.66M | -18.98M |
| CashFlowFromContinuingOperatingActivities | 64.87M | -5.63M | -41.66M | -18.98M |
| ChangeInWorkingCapital | -14.12M | -6.63M | -7.00K | -4.10M |
| ChangeInOtherWorkingCapital | 4.59M | 8.49M | 6.21M | |
| ChangeInOtherCurrentLiabilities | -1.29M | 852.00K | -608.00K | -1.13M |
| ChangeInOtherCurrentAssets | 1.58M | -588.00K | 1.61M | 751.00K |
| ChangeInPayablesAndAccruedExpense | -442.00K | 12.43M | 8.11M | 8.31M |
| ChangeInAccruedExpense | 3.93M | 6.73M | 7.53M | 8.49M |
| ChangeInPayable | -4.37M | 5.71M | 582.00K | -182.00K |
| ChangeInAccountPayable | -4.37M | 5.71M | 582.00K | -182.00K |
| ChangeInPrepaidAssets | -1.14M | -435.00K | -1.22M | -7.73M |
| ChangeInInventory | -193.00K | -3.96M | -1.68M | 327.00K |
| ChangeInReceivables | -12.64M | -14.93M | -6.22M | -4.63M |
| ChangesInAccountReceivables | -12.64M | -14.93M | -6.22M | -4.63M |
| OtherNonCashItems | 268.00K | 635.00K | -18.13M | |
| StockBasedCompensation | 50.32M | 51.22M | 36.32M | 21.74M |
| AmortizationOfSecurities | -6.68M | -5.49M | -1.37M | 0.00 |
| DeferredTax | 1.40M | -223.00K | -1.88M | -8.74M |
| DeferredIncomeTax | 1.40M | -223.00K | -1.88M | -8.74M |
| DepreciationAmortizationDepletion | 16.00M | 12.33M | 10.54M | 3.41M |
| DepreciationAndAmortization | 16.00M | 12.33M | 10.54M | 3.41M |
| AmortizationCashFlow | 11.11M | 9.01M | 8.27M | 1.96M |
| AmortizationOfIntangibles | 11.11M | 9.01M | 8.27M | 1.96M |
| Depreciation | 4.89M | 3.32M | 2.28M | 1.45M |
| OperatingGainsLosses | -555.00K | |||
| GainLossOnInvestmentSecurities | -555.00K | |||
| NetIncomeFromContinuingOperations | 18.25M | -57.47M | -67.14M | -31.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CSTL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|